Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy

World Journal of Gastroenterology

Volumn 12, Issue 40, 2006, Pages 6515-6521

  Yekebas, Emre F ^a   Bogoevski, Dean ^a   Bubenheim, Michael ^a   Link, Björn Christian ^a   Kaifi, Jussuf T ^a   Wachowiak, Robin ^a   Mann, Oliver ^a   Kutup, Asad ^a   Cataldegirmen, Guellue ^a   Wolfram, Lars ^a   Erbersdobler, Andreas ^a   Klein, Christoph ^b   Pantel, Klaus ^a   Izbicki, Jakob R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Micrometastases; Nodal microinvolvement; Pancreatic ductal adenocarcinoma

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARTICLE; BONE MARROW METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 33751008670     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i40.6515     Document Type: Article

References (39)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36
2. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ 1992; 120: 45-173
3. Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40: 549-558
4. Allison DC, Piantadosi S, Hruban RH, Dooley WC, Fishman EK, Yeo CJ, Lillemoe KD, Pitt HA, Lin P, Cameron JL. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998; 67: 151-159
5. Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, Gouma DJ, Obertop H. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995; 75: 2069-2076
6. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-633; discussion 633-636
7. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66
8. Mosca F, Giulianotti PC, Balestracci T, Di Candio G, Pietrabissa A, Sbrana F, Rossi G. Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997; 122: 553-566
9. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-458
10. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68-72; discussion 72-73
11. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-456
12. Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 1987; 13: 409-411
13. Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thetter O, Pichlmeier U, Schweiberer L, Riethmuller G, Pantel K. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994; 12: 1827-1832
14. Raymond WA, Leong AS. Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathology 1989; 21: 11-15
15. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol 1990; 43: 213-219
16. Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, Thetter O, Riethmuller G. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993; 53: 1027-1031
17. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986; 54: 631-636
18. Chen ZL, Perez S, Holmes EC, Wang HJ, Coulson WF, Wen DR, Cochran AJ. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 493-498
19. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992; 66: 523-527
20. Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198: 386-397
21. Casson AG, Rusch VW, Ginsberg RJ, Zankowicz N, Finley RJ. Lymph node mapping of esophageal cancer. Ann Thorac Surg 1994; 58: 1569-1570
22. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987; 47: 2883-2891
23. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, Riethmuller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165-173
24. Kasper M, Stosiek P, Typlt H, Karsten U. Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol 1987; 23: 137-147
25. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337: 1188-1194
26. Z'graggen K, Centeno BA, Fernandez-del Castillo C, Jimenez RE, Werner J, Warshaw AL. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery 2001; 129: 537-546
27. Kanemitsu K, Hiraoka T, Tsuji T, Inoue K, Takamori H. Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer. Pancreas 2003; 26: 315-321
28. Hosch SB, Knoefel WT, Metz S, Stoecklein N, Niendorf A, Broelsch CE, Izbicki JR. Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 1997; 15: 154-159
29. Vogel I, Kruger U, Marxsen J, Soeth E, Kalthoff H, Henne-Bruns D, Kremer B, Juhl H. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res 1999; 5: 593-599
30. Milsmann C, Fuzesi L, Werner C, Becker H, Horstmann O. Significance of occult lymphatic tumor spread in pancreatic cancer. Chirurg 2005; 76: 1064-1072
31. Bogoevski D, Yekebas EF, Schurr P, Kaifi JT, Kutup A, Erbersdobler A, Pantel K, Izbicki JR. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann Surg 2004; 240: 993-1000; discussion 1000-1001
32. Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999; 17: 19-24
33. Pedrazzoli S, Beger HG, Obertop H, Andren-Sandberg A, Fernandez-Cruz L, Henne-Bruns D, Luttges J, Neoptolemos JP. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg 1999; 16: 337-345
34. Hermanek P, Sobin LH. TNM classification of malignant tumors. 4th ed. New York: Springer, 1992
35. Klein JP, Moeschberger ML. SURVIVAL ANALYSIS Techniques for Censored and Truncated Data. New York: Springer, 1997
36. Cox DR. Regression Models and Life Tables (with discussion). J R Statist Soc 1972; 34: 187-220
37. Knisely AS. Cryptic tumor cells in lymph nodes of patients with esophageal cancer. N Engl J Med 1998; 338: 550
38. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-768
39. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210